LOS ANGELES, Sept 24 (Reuters) - Cytokinetics Inc said on Tuesday that interim results from a mid-stage trial of its experimental drug CK-1827452 showed that it induced significant improvements in patients with stable heart failure.
LOS ANGELES, Sept 24 (Reuters) - Cytokinetics Inc said on Tuesday that interim results from a mid-stage trial of its experimental drug CK-1827452 showed that it induced significant improvements in patients with stable heart failure.